MARKET

CODX

CODX

Co-Diagnostics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.89
+0.08
+0.63%
After Hours: 11.90 +0.01 +0.08% 19:30 01/20 EST
OPEN
11.90
PREV CLOSE
11.82
HIGH
12.11
LOW
11.41
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
30.99
52 WEEK LOW
1.100
MARKET CAP
336.12M
P/E (TTM)
13.28
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Why There's Still Need for Rapid Accessible Pathogen Testing, During and After the Crisis
, /PRNewswire/ -- As the most at-risk people begin to receive COVID-19 vaccinations, we are all looking forward to a post-pandemic world. As we transition back to something closer to normal life, however, the importance of rapid detection of any pathogen ...
PR Newswire - PRF · 01/13 14:00
Looking For The Best Biotech Stocks To Watch This Week? 3 Up 70%+ Last Week
Jan 11, 2021 (StockMarket.com via COMTEX) -- Are These The Top Biotech Stocks To Watch Now? 3 To Consider Biotech stocks are still amongst the top performers...
StockMarket.com · 01/11 16:40
Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference
, /PRNewswire/ -- Co-Diagnostics, Inc.(Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO will participate in a panel disc...
PR Newswire - PRF · 01/07 14:30
Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion ...
PR Newswire · 01/07 14:30
Co-Diagnostics to report highest quarterly revenue in Q4 2020
Citing preliminary internal financial reporting, Co-Diagnostics ([[CODX]] -0.9%) says it expects Q4 2020 revenue to be the highest quarterly revenue in the company’s history.Estimating a 20 – 25% growth over the Q3 2020
Seekingalpha · 01/06 15:18
Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products
, /PRNewswire/ -- Co-Diagnostics, Inc.(Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial ...
PR Newswire - PRF · 01/06 14:30
Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial reporting for the ...
PR Newswire · 01/06 14:30
Co-Diagnostics’ PCR test detects mutations in new coronavirus strain
Co-Diagnostics (CODX) has announced it has completed the principal design work for a PCR test to detect several mutations in the newly detected variant of SARS-CoV-2 known as VUI 202012/01.The new test
Seekingalpha · 12/22/2020 15:38
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CODX. Analyze the recent business situations of Co-Diagnostics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CODX stock price target is 31.00 with a high estimate of 43.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 111
Institutional Holdings: 8.06M
% Owned: 28.50%
Shares Outstanding: 28.27M
TypeInstitutionsShares
Increased
27
1.33M
New
37
170.35K
Decreased
19
512.73K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.34%
Healthcare Equipment & Supplies
+1.22%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dwight Egan
Chief Financial Officer/Secretary
Reed Benson
Chief Technology Officer
Brent Satterfield
Independent Director
Eugene Durenard
Independent Director
Edward Murphy
Independent Director
James Nelson
Independent Director
Richard Serbin
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
More

Webull offers kinds of Co-Diagnostics Inc stock information, including NASDAQ:CODX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CODX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CODX stock methods without spending real money on the virtual paper trading platform.